Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Aytu Biopharma (AYTU) Net Income towards Common Stockholders (2016 - 2025)

Aytu Biopharma has reported Net Income towards Common Stockholders over the past 15 years, most recently at $62000.0 for Q2 2025.

  • Quarterly Net Income towards Common Stockholders rose 105.0% to $62000.0 in Q2 2025 from the year-ago period, while the trailing twelve-month figure was $116000.0 through Dec 2025, up 108.7% year-over-year, with the annual reading at $620000.0 for FY2025, 118.65% up from the prior year.
  • Net Income towards Common Stockholders was $62000.0 for Q2 2025 at Aytu Biopharma, up from $54000.0 in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at $381000.0 in Q3 2024 and troughed at -$53.3 million in Q1 2022.
  • The 5-year median for Net Income towards Common Stockholders is -$1.2 million (2024), against an average of -$8.7 million.
  • Year-over-year, Net Income towards Common Stockholders crashed 546.8% in 2021 and then surged 158.89% in 2024.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$11.5 million in 2021, then soared by 42.04% to -$6.7 million in 2022, then skyrocketed by 87.46% to -$839000.0 in 2023, then surged by 114.66% to $123000.0 in 2024, then crashed by 49.59% to $62000.0 in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Net Income towards Common Stockholders are $62000.0 (Q2 2025), $54000.0 (Q1 2025), and $123000.0 (Q4 2024).